

Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a pilot trial

Lancet Respiratory Medicine, the
4, 390-398

DOI: [10.1016/s2213-2600\(16\)00100-4](https://doi.org/10.1016/s2213-2600(16)00100-4)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Asthma-like Features and Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1308-1309.	2.5	5
2	Asthma-like Features and Clinical Course of Chronic Obstructive Pulmonary Disease. An Analysis from the Hokkaido COPD Cohort Study. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1358-1365.	2.5	116
3	Serum eosinophils as a COPD biomarker: ready for prime time?. Lancet Respiratory Medicine, the, 2016, 4, 341-343.	5.2	7
4	Eosinófilos y corticoides inhalados en la enfermedad pulmonar obstructiva crónica. Archivos De Bronconeumologia, 2016, 52, 541.	0.4	0
5	A new alphabet for COPD care. European Respiratory Journal, 2016, 48, 972-975.	3.1	3
6	Indacaterol-Glycopyrronium for COPD. New England Journal of Medicine, 2016, 375, 897-900.	13.9	6
7	Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 541-549.	2.5	73
8	COPD therapy: if two is good, is three better?. Lancet, The, 2016, 388, 937-938.	6.3	4
9	Eosinophils and Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease. Archivos De Bronconeumologia, 2016, 52, 541.	0.4	0
10	The clinical profile of benralizumab in the management of severe eosinophilic asthma. Therapeutic Advances in Respiratory Disease, 2016, 10, 534-548.	1.0	31
11	Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review. Respiratory Research, 2016, 17, 112.	1.4	48
15	A new alphabet for COPD care: where "E" stands for España. European Respiratory Journal, 2017, 49, 1602067.	3.1	0
16	A new alphabet for COPD care: where "E" stands for España. European Respiratory Journal, 2017, 49, 1601970.	3.1	7
17	Personalised Medicine for Asthma and Chronic Obstructive Pulmonary Disease. Respiration, 2017, 93, 153-161.	1.2	25
18	Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1189-1197.	2.5	139
19	Asthma-chronic obstructive pulmonary disease overlap syndrome. Annals of Allergy, Asthma and Immunology, 2017, 118, 241-245.	0.5	16
20	Morning symptoms in COPD: a treatable yet often overlooked factor. Expert Review of Respiratory Medicine, 2017, 11, 311-322.	1.0	8
21	Stability of Blood Eosinophils in Patients with Chronic Obstructive Pulmonary Disease and in Control Subjects, and the Impact of Sex, Age, Smoking, and Baseline Counts. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1402-1404.	2.5	99

#	ARTICLE	IF	CITATIONS
22	Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 45, 19-33.	1.1	20
23	Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1181-1184.e7.	1.5	75
25	Chronic obstructive pulmonary disease. <i>Lancet, The</i> , 2017, 389, 1931-1940.	6.3	712
26	A Light in the Darkness? The FLAME Trial, Blood Eosinophils, and Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1125-1127.	2.5	5
27	Why choose tiotropium for my patient? A comprehensive review of actions and outcomes versus other bronchodilators. <i>Respiratory Medicine</i> , 2017, 128, 28-41.	1.3	15
28	Clinical characteristics of eosinophilic COPD versus COPD patients with a history of asthma. <i>Respiratory Research</i> , 2017, 18, 73.	1.4	30
29	Spanish COPD Guidelines (GesEPOC) 2017. Pharmacological Treatment of Stable Chronic Obstructive Pulmonary Disease. <i>Archivos De Bronconeumologia</i> , 2017, 53, 324-335.	0.4	30
30	Update in Chronic Obstructive Pulmonary Disease 2016. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 414-424.	2.5	10
31	Eosinophils in COPD: just another biomarker?. <i>Lancet Respiratory Medicine</i> , the, 2017, 5, 747-759.	5.2	160
32	Eosinophilia, Frequent Exacerbations, and Steroid Response in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1219-1221.	2.5	100
33	Through a glass darkly: inhaled corticosteroids, airway inflammation and COPD. <i>European Respiratory Journal</i> , 2017, 49, 1602201.	3.1	4
35	Predicting Corticosteroid Response in Chronic Obstructive Pulmonary Disease. Blood Eosinophils Gain Momentum. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1098-1100.	2.5	16
36	The Future of Biological Markers in COPD. <i>Archivos De Bronconeumologia</i> , 2017, 53, 541-542.	0.4	1
37	Is the Blood Eosinophil Count a Useful Biomarker in COPD? The devil is in the Details!. <i>Archivos De Bronconeumologia</i> , 2017, 53, 415-416.	0.4	3
38	Blood eosinophil count and exacerbation risk in patients with COPD. <i>European Respiratory Journal</i> , 2017, 50, 1700761.	3.1	64
39	Is the Blood Eosinophil Count a Useful Biomarker in COPD? The devil is in the Details!. <i>Archivos De Bronconeumologia</i> , 2017, 53, 415-416.	0.4	1
40	Futuro de los marcadores biológicos en la EPOC. <i>Archivos De Bronconeumologia</i> , 2017, 53, 541-542.	0.4	2
41	Individualizing the selection of long-acting bronchodilator therapy for patients with COPD: considerations in primary care. <i>Postgraduate Medicine</i> , 2017, 129, 725-733.	0.9	3

#	ARTICLE	IF	CITATIONS
42	CuÃa espaÃola de la enfermedad pulmonar obstructiva crÃnica (GesEPOC) 2017. Tratamiento farmacolÃgico en fase estable. Archivos De Bronconeumologia, 2017, 53, 324-335.	0.4	365
43	Should Patients Switched from D to B in the GOLD 2017 Classification be Discontinued from Inhaled Corticosteroids?. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2017, 14, 465-468.	0.7	20
44	Precision Medicine Urgency. Chest, 2017, 152, 227-231.	0.4	29
45	Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. European Respiratory Journal, 2017, 50, 1701162.	3.1	122
46	Triple Therapy in COPD: What We Know and What We Don't. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2017, 14, 648-662.	0.7	32
47	Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respiratory Medicine,the, 2017, 5, 956-967.	5.2	211
48	Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2017, 14, 641-647.	0.7	9
50	Emphysematous Phenotype is Characterized by Low Blood Eosinophils: A Cross-Sectional Study. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2017, 14, 635-640.	0.7	14
51	What Should Be the Cutoff Value of Blood Eosinophilia as a Predictor of Inhaled Corticosteroid Responsiveness in Patients with Chronic Obstructive Pulmonary Disease?. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1229-1230.	2.5	8
52	Global Initiative for Chronic Obstructive Lung Disease (GOLD) 20th Anniversary: a brief history of time. European Respiratory Journal, 2017, 50, 1700671.	3.1	69
53	A pragmatic approach to simplify inhaler therapy for COPD. Lancet Respiratory Medicine,the, 2017, 5, 679-681.	5.2	6
55	Reply: What Should Be the Cutoff Value of Blood Eosinophilia as a Predictor of Inhaled Corticosteroid Responsiveness in Patients with Chronic Obstructive Pulmonary Disease?. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1230-1231.	2.5	2
56	Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?. Respiratory Research, 2017, 18, 19.	1.4	7
57	Optimizing bronchodilation in the prevention of COPD exacerbations. Respiratory Research, 2017, 18, 125.	1.4	18
58	GOLD 2017 recommendations for COPD patients: toward a more personalized approach. COPD Research and Practice, 2017, 3, .	0.7	9
59	Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice. Npj Primary Care Respiratory Medicine, 2017, 27, 43.	1.1	53
61	CTS position statement: Pharmacotherapy in patients with COPDâ€”An update. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2017, 1, 222-241.	0.2	30
62	Peripheral eosinophil count as a biomarker for the management of COPD: not there yet. European Respiratory Journal, 2017, 50, 1702165.	3.1	15

#	ARTICLE	IF	CITATIONS
63	Withdrawal of ICS treatment in primary care: A practical guide. Practice Nursing, 2017, 28, 22-27.	0.1	4
64	Withdrawal of ICS treatment in primary care: A practical guide. NursePrescribing, 2017, 15, 86-90.	0.1	1
65	Fluticasone propionate/formoterol for COPD management: a randomized controlled trial. International Journal of COPD, 2017, Volume 12, 1961-1971.	0.9	22
66	Inhaled therapies in patients with moderate COPD in clinical practice: current thinking. International Journal of COPD, 2018, Volume 13, 45-56.	0.9	13
67	Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers?. International Journal of COPD, 2017, Volume 12, 1877-1882.	0.9	21
68	When is dual bronchodilation indicated in COPD?. International Journal of COPD, 2017, Volume 12, 2291-2305.	0.9	16
69	Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD. International Journal of COPD, 2017, Volume 12, 1819-1824.	0.9	81
70	A Belgian survey on the diagnosis of asthma–COPD overlap syndrome. International Journal of COPD, 2017, Volume 12, 601-613.	0.9	32
71	Recommendations for the pharmacological treatment of COPD: questions and answers. Jornal Brasileiro De Pneumologia, 2017, 43, 290-301.	0.4	20
72	Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respiratory Research, 2017, 18, 140.	1.4	52
73	A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease. Respiratory Research, 2017, 18, 198.	1.4	38
74	Comparison of the peripheral blood eosinophil count using near-patient testing and standard automated laboratory measurement in healthy, asthmatic and COPD subjects. International Journal of COPD, 2017, Volume 12, 2771-2775.	0.9	9
75	Clinical implications of blood eosinophil count in patients with non-asthma–COPD overlap syndrome COPD. International Journal of COPD, 2017, Volume 12, 2455-2464.	0.9	21
76	The effect of COPD severity and study duration on exacerbation outcome in randomized controlled trials. International Journal of COPD, 2017, Volume 12, 1457-1468.	0.9	7
77	POINT: Should an Attempt Be Made to Withdraw Inhaled Corticosteroids in All Patients With Stable GOLD 3 (30%Â%ÂFEV1Â< 50% Predicted) COPD? Yes. Chest, 2018, 153, 778-782.	0.4	7
78	A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD. Expert Opinion on Drug Safety, 2018, 17, 509-517.	1.0	6
79	Considerations for the Correct Diagnosis of COPD and Its Management With Bronchodilators. Chest, 2018, 154, 242-248.	0.4	16
80	Pharmacological treatment of COPD: the devil is always in the detail. European Respiratory Journal, 2018, 51, 1800263.	3.1	16

#	ARTICLE	IF	CITATIONS
81	Rebuttal From Dr Pavord. Chest, 2018, 153, 786-787.	0.4	0
82	A century of "intrinsic asthma"; Allergo Journal International, 2018, 27, 215-219.	0.9	9
83	COUNTERPOINT: Should an Attempt Be Made to Withdraw Inhaled Corticosteroids in All Patients With Stable GOLD 3 (30% \hat{A} % \hat{A} FEV $\hat{1}$ \hat{A} < 50% Predicted) COPD? No. Chest, 2018, 153, 782-784.	0.4	4
85	Definition and diagnosis of asthma" COPD overlap (ACO). Allergology International, 2018, 67, 172-178.	1.4	79
86	Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respiratory Medicine, the, 2018, 6, 117-126.	5.2	298
87	Assessing the healthcare resource use associated with inappropriate prescribing of inhaled corticosteroids for people with chronic obstructive pulmonary disease (COPD) in GOLD groups A or B: an observational study using the Clinical Practice Research Datalink (CPRD). Respiratory Research, 2018, 19, 63.	1.4	22
88	Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2018, 141, 2037-2047.e10.	1.5	138
89	Exacerbations of COPD. European Respiratory Review, 2018, 27, 170103.	3.0	189
91	Blood biomarkers in chronic airways diseases and their role in diagnosis and management. Expert Review of Respiratory Medicine, 2018, 12, 361-374.	1.0	10
92	Blood eosinophil levels as a biomarker in COPD. Respiratory Medicine, 2018, 138, 21-31.	1.3	86
93	Blood Leukocyte Concentrations, FEV $\hat{1}$ Decline, and Airflow Limitation. A 15-Year Longitudinal Study of World Trade Center"exposed Firefighters. Annals of the American Thoracic Society, 2018, 15, 173-183.	1.5	37
94	A century of "intrinsic asthma"; Allergo Journal, 2018, 27, 19-23.	0.1	2
95	Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids. International Journal of COPD, 2018, Volume 13, 3669-3676.	0.9	26
96	Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial. Respiratory Research, 2018, 19, 251.	1.4	28
97	Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research Statement. American Journal of Respiratory and Critical Care Medicine, 2018, 198, e116-e136.	2.5	49
98	Targeting Chronic Obstructive Pulmonary Disease Phenotypes, Endotypes, and Biomarkers. Annals of the American Thoracic Society, 2018, 15, S234-S238.	1.5	37
99	Toward effective prescription of inhaled corticosteroids in chronic airway disease. International Journal of COPD, 2018, Volume 13, 3419-3424.	0.9	2
100	An update on the use of inhaled therapy in COPD. Clinical Medicine, 2018, 18, 387-390.	0.8	2

#	ARTICLE	IF	CITATIONS
101	Personalisierte Medizin bei Asthma und chronisch-obstruktiver Lungenerkrankung. Karger Kompass Pneumologie, 2018, 6, 149-156.	0.0	0
102	Blood eosinophilia, use of inhaled corticosteroids, and risk of COPD exacerbations and mortality. Pharmacoepidemiology and Drug Safety, 2018, 27, 1191-1199.	0.9	17
103	Blood eosinophils and inhaled corticosteroids in patients with COPD: systematic review and meta-analysis. International Journal of COPD, 2018, Volume 13, 2775-2784.	0.9	33
104	Inhaled triple therapy in chronic obstructive pulmonary disease. Lancet, The, 2018, 392, 1112.	6.3	0
105	The dose of inhaled corticosteroids in patients with COPD: when less is better. International Journal of COPD, 2018, Volume 13, 3539-3547.	0.9	34
106	Primary care cohort study in the sequence of diagnosing chronic respiratory diseases and prescribing inhaled corticosteroids. Npj Primary Care Respiratory Medicine, 2018, 28, 37.	1.1	5
107	Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. Lancet Respiratory Medicine, the, 2018, 6, 855-862.	5.2	79
108	Longitudinal stability of blood eosinophil count strata in the COPD COSYCONET cohort. International Journal of COPD, 2018, Volume 13, 2999-3002.	0.9	21
109	Long-term effects of inhaled corticosteroids on bone mineral density in older women with asthma or COPD: a registry-based cohort study. Archives of Osteoporosis, 2018, 13, 116.	1.0	16
110	Shall We Focus on the Eosinophil to Guide Treatment with Systemic Corticosteroids during Acute Exacerbations of COPD?: PRO. Medical Sciences (Basel, Switzerland), 2018, 6, 74.	1.3	7
111	Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial. Lancet Respiratory Medicine, the, 2018, 6, 827-836.	5.2	46
112	Symptomatic COPD: is it time for triple therapy?. Lancet Respiratory Medicine, the, 2018, 6, 728-729.	5.2	1
113	Inhaled corticosteroids in COPD: friend or foe?. European Respiratory Journal, 2018, 52, 1801219.	3.1	166
114	Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study. European Respiratory Journal, 2018, 52, 1801334.	3.1	16
115	New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology. International Journal of COPD, 2018, Volume 13, 2805-2819.	0.9	5
116	Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy?. International Journal of COPD, 2018, Volume 13, 2587-2601.	0.9	69
118	Small airway inflammation and extrafine inhaled corticosteroids plus long-acting beta2-agonists formulations in chronic obstructive pulmonary disease. Respiratory Medicine, 2018, 143, 74-81.	1.3	10
119	Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1268-1278.	2.5	60

#	ARTICLE	IF	CITATIONS
120	Medication Regimens for Managing COPD Exacerbations. <i>Respiratory Care</i> , 2018, 63, 773-782.	0.8	3
121	An Update on the Global Initiative for Chronic Obstructive Lung Disease 2017 Guidelines With a Focus on Classification and Management of Stable COPD. <i>Respiratory Care</i> , 2018, 63, 749-758.	0.8	19
122	Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 329-339.	2.5	196
123	Overuse of inhaled corticosteroids in COPD: five questions for withdrawal in daily practice. <i>International Journal of COPD</i> , 2018, Volume 13, 2089-2099.	0.9	30
124	Circulating eosinophil levels do not predict severe exacerbations in COPD: a retrospective study. <i>ERJ Open Research</i> , 2018, 4, 00022-2018.	1.1	19
125	The distribution of blood eosinophil levels in a Japanese COPD clinical trial database and in the rest of the world. <i>International Journal of COPD</i> , 2018, Volume 13, 433-440.	0.9	9
126	Precision medicine in COPD: where are we and where do we need to go?. <i>European Respiratory Review</i> , 2018, 27, 180022.	3.0	61
127	Serial blood eosinophils and clinical outcome in patients with chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2018, 19, 134.	1.4	43
128	Blood Eosinophils as Biomarkers to Drive Treatment Choices in Asthma and COPD. <i>Current Drug Targets</i> , 2018, 19, 1882-1896.	1.0	60
129	A GATA3-specific DNzyme attenuates sputum eosinophilia in eosinophilic COPD patients: a feasibility randomized clinical trial. <i>Respiratory Research</i> , 2018, 19, 55.	1.4	29
130	Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective study. <i>Respiratory Medicine</i> , 2018, 142, 73-80.	1.3	20
131	Predictors of Asthma/COPD Overlap in FDNY Firefighters With World Trade Center Dust Exposure. <i>Chest</i> , 2018, 154, 1301-1310.	0.4	40
132	Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2018, Volume 13, 335-349.	0.9	108
133	Chronic obstructive pulmonary disease subpopulations and phenotyping. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1961-1971.	1.5	43
134	Clinical and molecular markers in COPD. <i>Pulmonology</i> , 2018, 24, 250-259.	1.0	20
135	To Withdraw or Not to Withdraw Inhaled Corticosteroids from Triple Therapy in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 292-294.	2.5	4
136	Current controversies in the stepping up and stepping down of inhaled therapies for COPD at the patient level. <i>Respirology</i> , 2018, 23, 818-827.	1.3	9
137	Clinical Approach to the Therapy of Asthma-COPD Overlap. <i>Chest</i> , 2019, 155, 168-177.	0.4	44

#	ARTICLE	IF	CITATIONS
138	Economic Impact of Reducing Inappropriate Inhaled Corticosteroids Use in Patients With Chronic Obstructive Pulmonary Disease: ISPOR's Guidance on Budget Impact in Practice. <i>Value in Health</i> , 2019, 22, 1092-1101.	0.1	12
139	Evaluation of exacerbations and blood eosinophils in UK and US COPD populations. <i>Respiratory Research</i> , 2019, 20, 178.	1.4	34
140	Blood eosinophils as biomarkers of therapeutic response to chronic obstructive pulmonary disease: Still work in progress. <i>European Journal of Internal Medicine</i> , 2019, 68, 1-5.	1.0	8
141	T2 Biologics for Chronic Obstructive Pulmonary Disease. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1405-1416.	2.0	37
143	Reassessing the Role of Eosinophils as a Biomarker in Chronic Obstructive Pulmonary Disease. <i>Journal of Clinical Medicine</i> , 2019, 8, 962.	1.0	18
144	Blood eosinophils could be useful as a biomarker in chronic obstructive pulmonary disease exacerbations. <i>International Journal of Clinical Practice</i> , 2019, 73, e13423.	0.8	12
145	A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6â€¹¼g and 160/18/9.6â€¹¼g using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol. <i>Respiratory Medicine</i> , 2019, 158, 59-66.	0.8	27
146	Decline of COPD exacerbations in clinical trials over two decades â€œ a systematic review and meta-regression. <i>Respiratory Research</i> , 2019, 20, 186.	1.4	10
147	The Airwaysâ€™ Mechanical Stress in Lung Disease: Implications for COPD Pathophysiology and Treatment Evaluation. <i>Canadian Respiratory Journal</i> , 2019, 2019, 1-8.	0.8	8
148	<p>A Framework For Step Down Or Therapeutic Re-Organization For Withdrawal Of Inhaled Corticosteroids In Selected Patients With COPD: A Proposal For COPD Management</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 2185-2193.	0.9	3
149	<p>Diagnosis and management of chronic obstructive pulmonary disease in Serbia: an expert group position statement</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 1993-2002.	0.9	14
150	<p>Real-life effectiveness of indacaterol–glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 249-260.	0.9	12
151	Blood Eosinophil Counts, Withdrawal of Inhaled Corticosteroids and Risk of COPD Exacerbations and Mortality in the Clinical Practice Research Datalink (CPRD). <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2019, 16, 152-159.	0.7	17
152	Perceptions of COPD patients of the proposed withdrawal of inhaled corticosteroids prescribed outside guidelines: A qualitative study. <i>Chronic Respiratory Disease</i> , 2019, 16, 147997311985588.	1.0	6
153	<p>Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 1267-1280.	0.9	24
154	Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base. <i>Therapeutic Advances in Respiratory Disease</i> , 2019, 13, 175346661985072.	1.0	4
155	Low and High Blood Eosinophil Counts as Biomarkers in Hospitalized Acute Exacerbations of COPD. <i>Chest</i> , 2019, 156, 92-100.	0.4	54
156	Stability of the Blood Eosinophilic Phenotype in Stable and Exacerbated COPD. <i>Chest</i> , 2019, 156, 456-465.	0.4	56

#	ARTICLE	IF	CITATIONS
157	Asthma–chronic obstructive pulmonary disease overlap: Diagnostic stability and inflammatory characteristics. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2271-2273.	2.7	0
158	&p'Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population&/p'. International Journal of COPD, 2019, Volume 14, 853-861.	0.9	20
159	Evaluating fluticasone furoate + vilanterol for the treatment of chronic obstructive pulmonary disease (COPD). Expert Opinion on Pharmacotherapy, 2019, 20, 1075-1085.	0.9	2
160	Inflammatory endotypes in COPD. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1249-1256.	2.7	147
161	&p'When to use single-inhaler triple therapy in COPD: a practical approach for primary care health care professionals&/p'. International Journal of COPD, 2019, Volume 14, 391-401.	0.9	20
162	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. European Respiratory Journal, 2019, 53, 1900164.	3.1	1,223
163	Change in inhaled corticosteroid treatment and COPD exacerbations: an analysis of real-world data from the KOLD/KOCOSS cohorts. Respiratory Research, 2019, 20, 62.	1.4	9
164	Diagnosis and Outpatient Management of Chronic Obstructive Pulmonary Disease. JAMA - Journal of the American Medical Association, 2019, 321, 786.	3.8	159
165	Adherence to the GOLD Guideline in COPD Management of South Korea: Findings from KOCOSS Study 2011–2018. Chonnam Medical Journal, 2019, 55, 47.	0.5	15
166	COPD treatment choices based on blood eosinophils: are we there yet?. Breathe, 2019, 15, 318-323.	0.6	12
167	Long-acting maintenance pharmacotherapy in chronic obstructive pulmonary disease. Respiratory Medicine: X, 2019, 1, 100009.	1.4	2
168	&p'Peripheral Blood Eosinophil as a Biomarker in Outcomes of Acute Exacerbation of Chronic Obstructive Pulmonary Disease&/p'. International Journal of COPD, 2019, Volume 14, 3003-3015.	0.9	27
169	Association between blood eosinophils and acute exacerbation of COPD risk in patients with COPD in primary care. Respiratory Medicine: X, 2019, 1, 100011.	1.4	3
170	Response. Chest, 2019, 156, 1277-1278.	0.4	0
171	Prevalence and Baseline Clinical Characteristics of Eosinophilic Chronic Obstructive Pulmonary Disease: A Meta-Analysis and Systematic Review. Frontiers in Medicine, 2019, 6, 282.	1.2	12
172	Blood eosinophil level to predict chronic obstructive pulmonary disease clinical outcomes. Chinese Medical Journal, 2019, 132, 2373-2375.	0.9	2
173	Inhaled corticosteroids and fractures in chronic obstructive pulmonary disease. Current Opinion in Pulmonary Medicine, 2019, 25, 165-172.	1.2	7
175	Management of chronic obstructive pulmonary disease–a position statement of the South African Thoracic Society: 2019 update. Journal of Thoracic Disease, 2019, 11, 4408-4427.	0.6	10

#	ARTICLE	IF	CITATIONS
176	Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee. <i>Annals of the American Thoracic Society</i> , 2019, 16, 29-39.	1.5	11
177	Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide as a combination therapy for chronic obstructive pulmonary disease. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 5-11.	1.0	2
180	Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. <i>Lancet Respiratory Medicine</i> , 2020, 8, 158-170.	5.2	69
181	Blood eosinophil count and airway epithelial transcriptome relationships in COPD versus asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 370-380.	2.7	37
182	Eosinophils in chronic obstructive pulmonary disease. <i>Current Opinion in Pulmonary Medicine</i> , 2020, 26, 169-174.	1.2	5
183	Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis. <i>Respiratory Research</i> , 2020, 21, 3.	1.4	49
184	Pharmacological treatment of stable COPD: need for a simplified approach. <i>Postgraduate Medicine</i> , 2020, 132, 126-131.	0.9	6
185	Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD. <i>Chest</i> , 2020, 157, 846-855.	0.4	57
186	Comorbid Conditions in Chronic Obstructive Pulmonary Disease: Potential Therapeutic Targets for Unmet Needs. <i>Journal of Clinical Medicine</i> , 2020, 9, 3078.	1.0	15
187	Prescribing Pathways to Triple Therapy: A Multi-Country, Retrospective Observational Study of Adult Patients with Chronic Obstructive Pulmonary Disease. <i>Pulmonary Therapy</i> , 2020, 6, 333-350.	1.1	15
188	Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease. <i>Clinics in Chest Medicine</i> , 2020, 41, 475-484.	0.8	7
189	Inhaled corticosteroid withdrawal may improve outcomes in elderly patients with COPD exacerbation: a nationwide database study. <i>ERJ Open Research</i> , 2020, 6, 00246-2019.	1.1	9
190	Asthma-chronic obstructive pulmonary disease overlap syndrome. <i>Current Opinion in Immunology</i> , 2020, 66, 161-166.	2.4	10
191	Should You Recommend Inhaled Corticosteroids for This Patient With Chronic Obstructive Pulmonary Disease?. <i>Annals of Internal Medicine</i> , 2020, 172, 735-742.	2.0	5
192	Effect of Inhaled Corticosteroid Withdrawal on Chronic Obstructive Pulmonary Disease Exacerbations in Patients Taking Triple Therapy at Baseline. <i>International Journal of COPD</i> , 2020, Volume 15, 2879-2888.	0.9	5
193	Prevalence of Asthma Characteristics in COPD Patients in a Dutch Well-Established Asthma/COPD Service for Primary Care. <i>International Journal of COPD</i> , 2020, Volume 15, 1601-1611.	0.9	4
194	Eosinophilia and parasitic infestations in patients with chronic obstructive pulmonary disease. <i>Scientific Reports</i> , 2020, 10, 12490.	1.6	7
195	Blood Eosinophil Count and Hospital Readmission in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. <i>International Journal of COPD</i> , 2020, Volume 15, 2629-2641.	0.9	13

#	ARTICLE	IF	CITATIONS
196	<p>Dual Bronchodilator in the Era of Triple Therapy</p>. International Journal of COPD, 2020, Volume 15, 2695-2705.	0.9	6
197	Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials. Respiratory Research, 2020, 21, 240.	1.4	29
198	<p>A Proposed Approach to Chronic Airway Disease (CAD) Using Therapeutic Goals and Treatable Traits: A Look to the Future</p>. International Journal of COPD, 2020, Volume 15, 2091-2100.	0.9	27
199	Role of Type2 Inflammatory Biomarkers in Chronic Obstructive Pulmonary Disease. Journal of Clinical Medicine, 2020, 9, 2670.	1.0	19
200	<p>Clinical and Economic Consequences of Inhaled Corticosteroid Doses and Particle Size in Triple Inhalation Therapy for COPD: Real-Life Study</p>. International Journal of COPD, 2020, Volume 15, 3291-3302.	0.9	4
201	Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline. European Respiratory Journal, 2020, 55, 2000351.	3.1	81
202	Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD. ERJ Open Research, 2020, 6, 00187-2019.	1.1	6
203	POINT: Are Eosinophils Useful for the Management of COPD? Yes. Chest, 2020, 157, 1073-1075.	0.4	6
204	High eosinophil blood counts are associated with a shorter length of hospital stay in exacerbated COPD patients â€“ a retrospective analysis. Respiratory Research, 2020, 21, 106.	1.4	17
205	Treatment with inhaled corticosteroids in chronic obstructive pulmonary disease. Journal of Thoracic Disease, 2020, 12, 1561-1569.	0.6	14
206	Elevated blood eosinophils in acute COPD exacerbations: better short- and long-term prognosis. European Clinical Respiratory Journal, 2020, 7, 1757274.	0.7	21
207	<p>Inhaled Corticosteroids in COPD: Trying to Make a Long Story Short</p>. International Journal of COPD, 2020, Volume 15, 821-829.	0.9	13
208	The cost-saving switch from inhaled corticosteroid-containing treatments to dual bronchodilation: a two-country projection of epidemiological and economic burden in chronic obstructive pulmonary disease. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662092680.	1.0	4
209	Improving the evaluation of COPD exacerbation treatment effects by accounting for early treatment discontinuations: a post-hoc analysis of randomized clinical trials. Respiratory Research, 2020, 21, 158.	1.4	3
210	<p>Comparing Randomized Controlled Trials and Real-World Studies in Chronic Obstructive Pulmonary Disease Pharmacotherapy</p>. International Journal of COPD, 2020, Volume 15, 1225-1243.	0.9	16
211	Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 660-671.	2.5	62
212	Blood cell for the differentiation of airway inflammatory phenotypes in COPD exacerbations. BMC Pulmonary Medicine, 2020, 20, 50.	0.8	13
213	Fractional Exhaled Nitric Oxide is Associated with the Severity of Stable COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2020, 17, 121-127.	0.7	12

#	ARTICLE	IF	CITATIONS
214	Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD. <i>European Respiratory Journal</i> , 2020, 55, 1902119.	3.1	26
215	Effects of long-term inhaled corticosteroid treatment on fragility fractures in older women: the Manitoba BMD registry study. <i>Osteoporosis International</i> , 2020, 31, 1155-1162.	1.3	1
216	Eosinophils in COPD—Current Concepts and Clinical Implications. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2565-2574.	2.0	20
217	Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits. <i>Thorax</i> , 2020, 75, 520-527.	2.7	97
218	Medicina personalizada para el asma y la enfermedad pulmonar obstructiva crónica. <i>Karger Kompass Neumologie</i> , 2020, 2, 10-17.	0.0	0
219	High suPAR and Low Blood Eosinophil Count are Risk Factors for Hospital Readmission and Mortality in Patients with COPD. <i>International Journal of COPD</i> , 2020, Volume 15, 733-743.	0.9	13
220	Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, e56-e69.	2.5	202
221	Inhaled Corticosteroid Treatment in Chronic Obstructive Pulmonary Disease (COPD): Boon or Bane?. <i>Journal of the American Board of Family Medicine</i> , 2020, 33, 289-302.	0.8	9
222	Endo-phenotyping of COPD patients. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 27-37.	1.0	20
223	Glycopyrrolate and formoterol fumarate for the treatment of COPD. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 13-25.	1.0	2
224	A perspective for chronic obstructive pulmonary disease (COPD) management: six key clinical questions to improve disease treatment. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 427-437.	0.9	5
225	Reducing and managing chronic obstructive pulmonary disease exacerbations with tiotropium+olodaterol. <i>Current Medical Research and Opinion</i> , 2021, 37, 275-284.	0.9	1
226	Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 611-620.	0.9	10
227	Advances in Chronic Obstructive Pulmonary Disease. <i>Annual Review of Medicine</i> , 2021, 72, 119-134.	5.0	33
228	Exacerbations of Lung Disease in Alpha-1 Antitrypsin Deficiency. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2021, 8, 162-176.	0.5	4
229	Blood eosinophil count-guided corticosteroid therapy and as a prognostic biomarker of exacerbations of chronic obstructive pulmonary disease: a systematic review and meta-analysis. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232110287.	1.1	13
230	Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study. <i>Respiratory Research</i> , 2021, 22, 25.	1.4	15
231	The prevalence and clinical features of chronic obstructive pulmonary disease patients with traits of asthma in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 25-35.	0.8	0

#	ARTICLE	IF	CITATIONS
232	Using Blood Eosinophil Count as a Biomarker to Guide Corticosteroid Treatment for Chronic Obstructive Pulmonary Disease. <i>Diagnostics</i> , 2021, 11, 236.	1.3	12
233	COPD patients prescribed inhaled corticosteroid in primary care: time for re-assessment based on exacerbation rate and blood eosinophils?. <i>Respiratory Research</i> , 2021, 22, 54.	1.4	2
234	Targeting eosinophils in respiratory diseases: Biological axis, emerging therapeutics and treatment modalities. <i>Life Sciences</i> , 2021, 267, 118973.	2.0	16
235	Association Between Blood Eosinophils and Mortality in Critically Ill Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Retrospective Cohort Study. <i>International Journal of COPD</i> , 2021, Volume 16, 281-288.	0.9	9
236	Do Circulating Monocytes Promote and Predict IPF Progression?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 9-11.	2.5	3
237	Blood eosinophils in COPD to predict exacerbations and inform inhaled corticosteroid use: Need for further evidence?. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2021, 5, 136-149.	0.2	0
238	Blood eosinophils in COPD to inform inhaled corticosteroid use: Ready to be used in clinical practice. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2021, 5, 132-135.	0.2	0
239	The association between eosinophilic exacerbation and eosinophilic levels in stable COPD. <i>BMC Pulmonary Medicine</i> , 2021, 21, 74.	0.8	7
240	A Review of Clinical Trials That Contributed to Chronic Obstructive Pulmonary Disease Treatment Protocols. <i>Cureus</i> , 2021, 13, e14618.	0.2	1
241	Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact. <i>Respirology</i> , 2021, 26, 532-551.	1.3	67
242	Single inhaler triple therapy in COPD – all that glitters is not gold. <i>Monaldi Archives for Chest Disease</i> , 2021, 91, .	0.3	1
243	Pharmacological treatment of stable chronic obstructive pulmonary disease. <i>Respirology</i> , 2021, 26, 643-651.	1.3	21
244	Peripheral Blood Eosinophils and Nine Years Mortality in COPD Patients. <i>International Journal of COPD</i> , 2021, Volume 16, 979-985.	0.9	9
246	Upper airway symptoms associate with the eosinophilic phenotype of COPD. <i>ERJ Open Research</i> , 2021, 7, 00184-2021.	1.1	5
247	Triple versus LAMA/LABA combination therapy for patients with COPD: a systematic review and meta-analysis. <i>Respiratory Research</i> , 2021, 22, 183.	1.4	15
248	Blood eosinophil counts in the general population and airways disease: a comprehensive review and meta-analysis. <i>European Respiratory Journal</i> , 2022, 59, 2004590.	3.1	37
249	Circulating blood eosinophils as a biomarker for variable clinical presentation and therapeutic response in patients with chronic pruritus of unknown origin. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2513-2516.e2.	2.0	9
250	Real-world effectiveness of early intervention with fixed-dose tiotropium/olodaterol vs tiotropium in Japanese patients with COPD: a high-dimensional propensity score-matched cohort analysis. <i>Respiratory Research</i> , 2021, 22, 180.	1.4	4

#	ARTICLE	IF	CITATIONS
251	ACO (Asthmaâ€œCOPD Overlap) Is Independent from COPD: The Case Against. <i>Diagnostics</i> , 2021, 11, 1189.	1.3	4
252	Impacts of lipid-related metabolites, adiposity, and genetic background on blood eosinophil counts: the Nagahama study. <i>Scientific Reports</i> , 2021, 11, 15373.	1.6	5
253	Step-Up and Step-Down Treatment Approaches for COPD: A Holistic View of Progressive Therapies. <i>International Journal of COPD</i> , 2021, Volume 16, 2065-2076.	0.9	1
254	Burden of Disease Among Exacerbating Patients with COPD Treated with Triple Therapy in Spain. <i>International Journal of COPD</i> , 2021, Volume 16, 2149-2161.	0.9	2
255	Biomarkers in Chronic Obstructive Pulmonary Disease: Emerging Roles of Eosinophils and Procalcitonin. <i>Journal of Innate Immunity</i> , 2022, 14, 89-97.	1.8	4
256	Treatment Response Biomarkers in Asthma and COPD. <i>Diagnostics</i> , 2021, 11, 1668.	1.3	5
257	Update on guidelines for the treatment of COPD in Taiwan using evidence and GRADE system-based recommendations. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 1821-1844.	0.8	10
258	Inflammatory and Immune Mechanisms in COPD. , 2022, , 549-558.		0
259	Biomarkers in COPD. , 2021, , .		1
260	The lower the eosinophils, the stronger the inflammatory response? The relationship of different levels of eosinophils with the degree of inflammation in acute exacerbation chronic obstructive pulmonary disease (AECOPD). <i>Journal of Thoracic Disease</i> , 2021, 13, 232-243.	0.6	13
261	Pulmonary hypertension in eosinophilic <i>versus</i> noneosinophilic COPD. <i>ERJ Open Research</i> , 2021, 7, 00772-2020.	1.1	4
262	Stability of Blood Eosinophil Count in Patients with COPD in the UK Clinical Practice Research Datalink. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2017, 14, 382-388.	0.7	54
263	High eosinophil counts predict decline in FEV₁: results from the CanCOLD study. <i>European Respiratory Journal</i> , 2021, 57, 2000838.	3.1	29
264	A machine learning approach to triaging patients with chronic obstructive pulmonary disease. <i>PLoS ONE</i> , 2017, 12, e0188532.	1.1	68
266	Blood Eosinophil Counts in Chronic Obstructive Pulmonary Disease: A Biomarker of Inhaled Corticosteroid Effects. <i>Tuberculosis and Respiratory Diseases</i> , 2020, 83, 185-194.	0.7	14
267	Allergy and Chronic Obstructive Pulmonary Disease. <i>Chinese Medical Journal</i> , 2017, 130, 2017-2020.	0.9	2
268	Novel pharmacological strategies to treat cognitive dysfunction in chronic obstructive pulmonary disease. , 2022, 233, 108017.		8
269	Narrative Literature Review Guided Approach of Inhaled Corticosteroid de-escalation in Chronic Obstructive Pulmonary Disease. <i>Journal of Pharmacy Practice</i> , 2021, , 089719002110537.	0.5	1

#	ARTICLE	IF	CITATIONS
270	The Role of Blood Eosinophils in the Management of COPD: An Attempt to Answer the Important Clinical Questions. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2021, 18, 690-699.	0.7	2
271	Eosinophilic endotype of chronic obstructive pulmonary disease: similarities and differences from asthma. Korean Journal of Internal Medicine, 2021, 36, 1305-1319.	0.7	5
272	The Use of Inhaled Corticosteroids for Patients with COPD Who Continue to Smoke Cigarettes: An Evaluation of Current Practice. American Journal of Medicine, 2022, 135, 302-312.	0.6	10
273	Inhaled steroids / long-acting β_2 -agonists in treatment of chronic obstructive pulmonary disease: the discussion goes on. Pulmonologiya, 2016, 26, 357-363.	0.2	1
274	INDIVIDUALIZED APPROACH, EVIDENCE, PRACTICE (BASED ON PROCEEDINGS OF THE 26TH NATIONAL) Tj ETQq0 0,0 rgBT /Qoverlock 10	0.2	0
276	Drugs for chronic obstructive pulmonary disease. Australian Prescriber, 2017, 40, 15-19.	0.5	8
277	A role of budesonide/formoterol fixed combination in the treatment of stable chronic obstructive pulmonary disease. A conclusion of the Expert Council of the Volga Federal district of Russia. Pulmonologiya, 2017, 27, 114-121.	0.2	3
278	Anti-inflammatory treatment of stable COPD - current trends and recommendations for clinical practiceExperts statement. Klinicka Farmakologie A Farmacie, 2017, 31, 22-30.	0.1	0
280	EOSINOPHILS AS A NON-INVASIVE MARKER TO ASSESS INFLAMMATORY ACTIVITIES INÂTHOSE SUFFERING FROM CHRONIC OBSTRUCTIVE PULMONARY DISEASE. Tuberculosis and Lung Diseases, 2018, 96, 54-61.	0.2	2
281	Possibilities to prevent acute exacerbation of chronic obstructive pulmonary disease using inhalational therapy. A Report of Expert Panel of Russian Respiratory Society. Pulmonologiya, 2018, 28, 368-380.	0.2	3
282	Possibilities and limitations of inhaled corticosteroids in the treatment of chronic obstructive pulmonary disease. Pulmonologiya, 2018, 28, 602-612.	0.2	2
283	COPD: Neuer GOLD-Standard betont die individualisierte Therapie. Deutsches Ärzteblatt International, 0, , .	0.6	1
284	Triple therapy in chronic obstructive pulmonary disease. Pulmonologiya, 2019, 29, 199-206.	0.2	5
285	Withdrawal of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Pulmonologiya, 2019, 29, 334-345.	0.2	1
286	Initial inhaler choice in COPD: real-world evidence. Breathe, 2019, 15, 350-352.	0.6	0
287	Individual trajectory-based care for COPD: getting closer, but not there yet. ERJ Open Research, 2021, 7, 00451-2021.	1.1	2
288	Effect of Adding Inhaled Corticosteroid to Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist Therapy Among Patients With Chronic Obstructive Pulmonary Disease. Cureus, 2021, 13, e19168.	0.2	0
289	COPD Pharmacological Management Update. , 0, , .		0

#	ARTICLE	IF	CITATIONS
290	COPD in Germany: Use of Diagnostic Measures Including Blood Eosinophil Counts in Daily Practice. <i>Pneumologie</i> , 2021, 75, 344-352.	0.1	1
291	Pharmacotherapy of chronic obstructive pulmonary disease: Therapeutic considerations with a focus on inhaled corticosteroids. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2020, 62, e1-e6.	0.2	0
292	COPD Phenotyping. <i>Respiratory Medicine</i> , 2020, , 225-239.	0.1	0
293	COPD: treatment and prevention of pulmonary exacerbations. , 0, , 147-166.		0
294	Inhaled corticosteroids in COPD: Personalising the therapeutic choice. <i>African Journal of Thoracic and Critical Care Medicine</i> , 2018, 24, .	0.3	0
295	Short-term responses to high-dose inhaled corticosteroid treatment in patients with chronic obstructive pulmonary disease with a fractional nitric oxide concentration over 35 parts per billion: A single-centre pre- post study. <i>Archives of Asthma Allergy and Immunology</i> , 2020, 4, 012-017.	0.1	0
296	Eosinophilic COPD. , 2022, , 100-118.		1
297	IgE is associated with exacerbations and lung function decline in COPD. <i>Respiratory Research</i> , 2022, 23, 1.	1.4	21
298	Blood Eosinophils in Chinese COPD Participants and Response to Treatment with Combination Low-Dose Theophylline and Prednisone: A Post-Hoc Analysis of the TASC Trial. <i>International Journal of COPD</i> , 2022, Volume 17, 273-282.	0.9	0
299	Blood Eosinophils in Chronic Obstructive Pulmonary Disease: Is There Enough Evidence?. <i>US Respiratory & Pulmonary Diseases</i> , 2021, 6, 31.	0.2	1
300	Use of single-inhaler triple therapy in the management of obstructive airway disease: Indian medical experts' review. <i>ERJ Open Research</i> , 2022, 8, 00556-2021.	1.1	2
301	Longitudinal changes in forced expiratory volume in 1Âs in patients with eosinophilic chronic obstructive pulmonary disease. <i>BMC Pulmonary Medicine</i> , 2022, 22, 91.	0.8	1
302	Incorporating Biomarkers in COPD Management: The Research Keeps Going. <i>Journal of Personalized Medicine</i> , 2022, 12, 379.	1.1	12
303	Asthma-COPD Overlap. <i>Current Pulmonology Reports</i> , 2022, 11, 1-14.	0.5	1
304	Evidence-based management approaches for patients with severe chronic obstructive pulmonary disease (COPD): A practice review. <i>Palliative Medicine</i> , 2022, , 026921632210796.	1.3	5
305	COPD â€ do the right thing. <i>BMC Family Practice</i> , 2021, 22, 244.	2.9	23
306	Measurement of Blood Eosinophils in Asthma and Chronic Obstructive Pulmonary Disease. <i>Internal Medicine</i> , 2023, 62, 21-25.	0.3	4
309	Quantitative assessment of emphysema and bronchial wall thickness in patients with stable chronic obstructive pulmonary disease: comparison between the eosinophilic and non-eosinophilic phenotypes. <i>Radiologia Brasileira</i> , 0, , .	0.3	1

#	ARTICLE	IF	CITATIONS
310	A systematic review of blood eosinophils and continued treatment with inhaled corticosteroids in patients with COPD. <i>Respiratory Medicine</i> , 2022, 198, 106880.	1.3	6
311	Chronic obstructive pulmonary disease. <i>Lancet, The</i> , 2022, 399, 2227-2242.	6.3	228
312	Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD "real world" study. <i>Respiratory Research</i> , 2022, 23, 109.	1.4	4
313	Relationship between prior inhaled corticosteroid use and benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS study. <i>Respiratory Medicine</i> , 2022, 197, 106857.	1.3	3
314	Cost-consequence analysis of COPD treatment according to NICE and GOLD recommendations compared with current clinical practice in the UK. <i>BMJ Open</i> , 2022, 12, e059158.	0.8	3
315	Use of Inhaled Corticosteroids and Risk of Acquiring <i>Haemophilus influenzae</i> in Patients with Chronic Obstructive Pulmonary Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 3539.	1.0	5
316	Federal guidelines on diagnosis and treatment of chronic obstructive pulmonary disease. <i>Pulmonologiya</i> , 2022, 32, 356-392.	0.2	24
317	Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review. <i>Respiratory Research</i> , 2022, 23, .	1.4	20
318	Clinical Characteristics and Outcome Related to Blood Eosinophilic Chronic Obstructive Pulmonary Disease (COPD) Patients. <i>Cureus</i> , 2022, , .	0.2	0
319	Clinical and Economic Impact of Long-Term Inhaled Corticosteroid Withdrawal in Patients with Chronic Obstructive Pulmonary Disease Treated with Triple Therapy in Spain. <i>International Journal of COPD</i> , 0, Volume 17, 2161-2174.	0.9	0
321	Managing chronic obstructive pulmonary disease in primary care: clinical characteristics of patients receiving inhaled corticosteroids. <i>Journal of Pharmacy Practice and Research</i> , 0, , .	0.5	0
322	BÁCH CÁU U AI TOAN MÃU " DÁU ÁN SINH HÁ»EC TIÃŠN LÊ"Á»CNG ÄÁ»CT CÁP BÁ»†NH PHÁ»"I TÁ»C NGHÁ»/4N MÁ»NÃNH. , 20		
323	Hospitalization for chronic obstructive pulmonary disease and pneumonia: association with the dose of inhaled corticosteroids. A nation-wide cohort study of 52-100 outpatients. <i>Clinical Microbiology and Infection</i> , 2023, 29, 523-529.	2.8	5
324	De-Prescribing Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease: A Narrative Review. <i>Journal of Pharmacy Practice</i> , 2024, 37, 478-484.	0.5	0
325	Blood eosinophil count variability in chronic obstructive pulmonary disease and severe asthma. <i>Allergy International</i> , 2023, 72, 402-410.	1.4	6
326	Practical Recommendations for a Selection of Inhaled Corticosteroids in COPD: A Composite ICO Chart. <i>Biomolecules</i> , 2023, 13, 213.	1.8	0
327	ERJ advances: state of the art in definitions and diagnosis of COPD. <i>European Respiratory Journal</i> , 2023, 61, 2202318.	3.1	5
328	Blood Eosinophils and Clinical Outcomes in Inpatients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Prospective Cohort Study. <i>International Journal of COPD</i> , 0, Volume 18, 169-179.	0.9	2

#	ARTICLE	IF	CITATIONS
329	Impact of triple therapy on mortality in COPD. <i>Breathe</i> , 2023, 19, 220260.	0.6	0
330	Inhaled Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease and Risk of Acquiring <i>Streptococcus pneumoniae</i> Infection. A Multiregional Epidemiological Study. <i>International Journal of COPD</i> , 0, Volume 18, 373-384.	0.9	2
341	Chronic Obstructive Pulmonary Disease (COPD). , 2023, , 1-42.		0
348	The future drug treatment of COPD. , 2024, , 233-254.		0